ifct-1803 lorlatu cohort: real-world evidence supporting lorlatinib in alk nsclc
Published 2 years ago • 126 plays • Length 3:46Download video MP4
Download video MP3
Similar videos
-
1:35
real-world toxicities associated with lorlatinib in alk nsclc
-
2:37
crown: lorlatinib in treatment-naïve patients with alk-positive advanced nsclc
-
1:24
real world evidence in lung cancer: pros, cons & potential
-
4:11
crown: biomarkers for lorlatinib response in patients with alk nsclc
-
9:33
second-line brigatinib for alk/ros1-rearranged nsclc
-
0:59
dr. johung on prognosis of patients with alk-rearranged nsclc and brain metastases
-
1:30
efficacy of lorlatinib in nsclc post-second generation alk tki
-
1:46
is lorlatinib a better option for nsclc?
-
5:28
crown study: lorlatinib vs crizotinib in 1l nsclc
-
2:39
esmo 2020 highlights on 1st line lorlatinib for alk nsclc: the crown study
-
3:34
alk-positive nsclc: the role of treatment selection and sequencing
-
4:38
patterns of progression on crizotinib for alk nsclc
-
0:58
alk positive dr. vincent lam's vaccine research
-
1:06
comparing alectinib versus crizotinib in alk nsclc
-
1:22
dr. liu on navigating the frontline treatment of alk nsclc
-
1:38
experts on alk non-small cell lung cancer
-
2:10
molecularly-guided treatment of advanced nsclc: alk inhibitor sequencing
-
8:16
alta ii trial of brigatinib in alk-rearranged nsclc
-
2:30
alk non-small cell lung cancer patient video: miriam & joel